Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
LYEL
Home
/
LYEL

NASDAQ
$15.43
$15.43

Overview

Price performance
Low
$12.12
High
$16.65
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
15.43
4.66 (43.27%)
Average, 50 days
$10.85
$16.74
Open
$12.12
Previous close
$10.77
52-week high
$45.00
Dec 22, 2025 (11 months ago)
52-week low
$7.20
Oct 14, 2026 (22 days ago)
114.31%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
378.11M
Volume
1 099 750
Total Return (3M)
13.46%
Total Return (1Y)
-3.26%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
lyell.com
About
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Frequently asked questions

LYEL · Lyell Immunopharma, Inc.

01What is Lyell Immunopharma, Inc. stock price today?

The current price of LYEL is $15.43 — it has increased by 43.27% since the previous close. Data as of Nov 4, 2026.

02Is Lyell Immunopharma, Inc. stock price growing?

LYEL is up 37.03% over the past week, up 66.63% over the past month and down 3.26% over the past year. The price is below its 200-day moving average of $16.74.

03What do analysts say about LYEL stock?

Of the 8 analysts covering Lyell Immunopharma, Inc., 2 rate it a strong buy, 5 rate it a buy and 1 rates it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

04What is Lyell Immunopharma, Inc. market cap?

Lyell Immunopharma, Inc. has a market capitalization of $378.11M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

05What were Lyell Immunopharma, Inc. earnings last quarter?

In its most recent quarterly report, Lyell Immunopharma, Inc. posted a loss of $1.86 per share against an estimate of -$2.06, beating expectations by 9.71%. Upcoming reports are listed in the earnings calendar.

06What is Lyell Immunopharma, Inc. revenue for the last quarter?

Lyell Immunopharma, Inc. reported revenue of $3K in its most recent quarter, which has decreased by 80.00% compared with the same quarter a year earlier. Analysts had expected $4.6K.

07Does Lyell Immunopharma, Inc. pay dividends?

Lyell Immunopharma, Inc. has not paid any dividends over the past year.

08How volatile is LYEL stock?

In the latest trading session LYEL moved between $12.12 and $16.65, a range of 29.36% of its current price.

09Should I invest in Lyell Immunopharma, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Lyell Immunopharma, Inc. shows a buy rating today and a buy rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

10What are LYEL stock 52-week high and low?

Over the past 52 weeks LYEL has traded between $7.20 and $45.00. The current price is 65.71% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.